GMDP augments antitumor action of the CP/TNFα combination in vivo

Abstract We have shown that glucosaminyl muramyl dipeptide (GMDP) has been augmented the antitumor action of chemotherapy drug cisplatin and tumor necrosis factor-α (TNFα) on the Ehrlich ascites carcinoma and melanoma B-16 mouse tumor models. The doses of cisplatin, TNFα and GMDP and also the condit...

Full description

Saved in:

Bibliographic Details
Published in:	Biomedicine & pharmacotherapy Vol. 64; no. 4; pp. 240 - 248
Main Authors:	Petrova, Elena E, Simonova, Maria A, Komaleva, Ravilya L, Britsina, Marina V, Andronova, Tatiana M, Nesmeyanov, Vladimir A, Valyakina, Tatiana I
Format:	Journal Article
Language:	English
Published:	Elsevier SAS 01-04-2010
Subjects:	Chemotherapy Glucosaminyl muramyl dipeptide Internal Medicine Medical Education Tumor necrosis factor Tumor necrosis factor Glucosaminyl muramyl dipeptide Chemotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract We have shown that glucosaminyl muramyl dipeptide (GMDP) has been augmented the antitumor action of chemotherapy drug cisplatin and tumor necrosis factor-α (TNFα) on the Ehrlich ascites carcinoma and melanoma B-16 mouse tumor models. The doses of cisplatin, TNFα and GMDP and also the conditions of the drugs combination injection provided 100% survival of mice with Ehrlich ascites carcinoma were found. Furthermore, it was shown first that GMDP has been decreased toxicity of the cisplatin/TNFα combination and normalized the changes in the experimental mice hematological parameters which were produced by the CP/TNFα combination.
ISSN:	0753-3322 1950-6007
DOI:	10.1016/j.biopha.2009.06.019